Overview

JT001 (VV116) for the Treatment of COVID-19

Status:
Not yet recruiting
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of JT001 (VV116) in participants with mild to moderate COVID-19.
Phase:
Phase 3
Details
Lead Sponsor:
Shanghai Vinnerna Biosciences Co., Ltd.
Collaborator:
Sponsor GmbH